Soleil Boughton Sells 4,812 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 4,812 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $118,808.28. Following the completion of the transaction, the insider owned 308,831 shares in the company, valued at approximately $7,625,037.39. This represents a 1.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Hims & Hers Health Price Performance

Shares of HIMS stock opened at $24.13 on Friday. The firm has a market cap of $5.50 billion, a price-to-earnings ratio of 47.32, a PEG ratio of 2.60 and a beta of 2.55. Hims & Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $70.43. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80. The stock has a 50-day moving average price of $22.99 and a 200 day moving average price of $36.89.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.06. The company had revenue of $617.82 million for the quarter, compared to the consensus estimate of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. During the same period in the prior year, the company posted $0.11 EPS. The company’s revenue was up 28.4% compared to the same quarter last year. Research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Partnership with Novo Nordisk opens a pre‑launch waitlist for Ozempic and Wegovy via HIMS’ telehealth platform — this can drive meaningful Rx volume and recurring revenue if patient conversion and margins scale. Read More.
• Positive Sentiment: Sell‑side notes and at least one upgraded target point to upside tied to GLP‑1 access and growth execution — helpful for medium‑term sentiment if HIMS delivers on metrics. Read More.
• Neutral Sentiment: Value/investment write‑ups are highlighting HIMS alongside telehealth and weight‑loss beneficiaries — useful context but not an immediate catalyst. Read More.
• Negative Sentiment: Material insider selling: COO Michael Chi disclosed sale of ~97k shares and other executives sold smaller stakes on March 17 — large insider dispositions can sap investor confidence and put downward pressure on the stock. Read More.
• Negative Sentiment: Short‑term market reaction: HIMS underperformed the broader market in the latest session, reflecting immediate selling despite the Novo partnership. Read More.
• Negative Sentiment: GLP‑1 pricing risk: analysts warn escalating price competition between Novo Nordisk and Eli Lilly could accelerate discounts and compress margins/ARPU for telehealth distributors like HIMS. Read More.

Wall Street Analyst Weigh In

A number of research firms have commented on HIMS. Bank of America raised shares of Hims & Hers Health from an “underperform” rating to a “neutral” rating and lifted their target price for the stock from $12.50 to $23.00 in a report on Tuesday, March 10th. Barclays increased their price target on Hims & Hers Health from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, March 11th. Morgan Stanley reduced their price target on Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $25.00 to $28.00 and gave the stock a “hold” rating in a research note on Tuesday, March 10th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $31.29.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Hims & Hers Health by 7.2% during the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after purchasing an additional 1,407,651 shares in the last quarter. Capital World Investors increased its position in shares of Hims & Hers Health by 1.2% in the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock valued at $1,065,399,000 after buying an additional 223,892 shares in the last quarter. Farallon Capital Management LLC increased its position in shares of Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after buying an additional 2,533,271 shares in the last quarter. State Street Corp raised its stake in Hims & Hers Health by 1.8% during the 4th quarter. State Street Corp now owns 7,305,525 shares of the company’s stock worth $237,210,000 after buying an additional 132,311 shares during the period. Finally, Geode Capital Management LLC raised its stake in Hims & Hers Health by 12.4% during the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock worth $183,485,000 after buying an additional 608,950 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.